Alpha emitter radium-223 and survival in metastatic prostate cancer
about
Immunobiology and immunotherapy in genitourinary malignanciesGaleterone for the treatment of advanced prostate cancer: the evidence to dateFrom palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastasesImmune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?A Perspective of Immunotherapy for Prostate CancerClinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastasesTargeted Radionuclide Therapy: Practical Applications and Future ProspectsMolecular signaling involving intrinsically disordered proteins in prostate cancerFuture directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigmSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerProstate cancer is not breast cancerTargeted Radionuclide Therapy of Human TumorsPatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceSequence of treatment in locally advanced and metastatic renal cell carcinomaDiagnostic Performance of Diffusion-weighted Magnetic Resonance Imaging in Bone Malignancy: Evidence From a Meta-AnalysisComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerMinimally invasive local treatments for bone and pulmonary metastasesImmunotherapy for prostate cancer: recent developments and future challengesSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Current clinical challenges in prostate cancerTherapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerWell-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastasesHealth Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the LiteratureQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerSequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapyTargeting the adaptive molecular landscape of castration-resistant prostate cancerWhat is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidenceRadium-223 and metastatic castration-resistant prostate cancer: All that glitters is not goldRadioisotopes in management of metastatic prostate cancerMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Androgen deprivation therapy as backbone therapy in the management of prostate cancerEpigenetic modulators as therapeutic targets in prostate cancerImmunotherapy in metastatic prostate cancerRadionuclides
P2860
Q26738668-F47FE672-BB1B-4180-8E99-23517712151BQ26739887-5964138D-2E4B-4429-BB40-69B347E7CE5EQ26740064-B707F62D-30FE-4E4C-AFC7-BE062B287C0AQ26740601-70BB9CA7-DD96-4E9E-B64C-F92FF823D832Q26741277-2B37308B-41BF-4581-8B26-75BFC71D3A4CQ26744355-8AF1363E-3C66-452C-89FF-FA9BF23DE4BBQ26745926-EDC36BE7-E25F-4700-8B86-F4FCB7D4F45EQ26747089-86875B07-8A9B-4D7D-832F-9290EB43D14EQ26747566-AD65944C-FE6E-4497-85CA-AAA8C8AC876EQ26747699-92E2CBDA-027F-4037-B08F-8BC3CC308370Q26747782-E87A0B57-0714-4425-BA70-5B37C103C2A0Q26751354-EF225079-99B8-4855-A31D-4B7069884004Q26771267-DA5796DB-93E8-40EA-943B-FC03A521A99EQ26772883-E7FB5B5F-E0A8-46ED-82E3-DADB988A3BF2Q26773653-3F263650-CBFC-42EF-80E0-E0913C48724BQ26777520-8BB2352E-9592-44E9-B0B5-8B2B2A461C11Q26785658-4C9EF1C6-F8CC-4B38-A437-F40E529E5288Q26786543-65D6C44A-480A-4A9B-8C53-941C8FFFEAFDQ26796568-035B6976-AC3E-4BF3-A5ED-9D0909ED8F10Q26823733-2EFD75BA-A6FF-452F-BE0B-BB09F2F7AB6FQ26849767-8DCCA7C2-6075-4743-A735-78CB57A09225Q26852388-0B7849FA-67B3-4B1E-9411-CEC212042871Q26852544-AB19408A-4989-4682-B4E7-6FB3A80CE201Q26861575-A6571340-A3CB-4BB3-8EA1-F9F58B175F4DQ26866036-D0294F5C-9214-40B6-8834-3C9C7FC163F0Q27002342-355B78D2-06AB-46A8-B2EB-AB0DEAE1A7D1Q27002591-CA627649-51B9-413A-AA45-5839D890B4AAQ27004566-00C1180A-087A-4CE7-98D5-F6D1C05D7732Q27011642-AC0AE298-8D95-4DAD-95B7-21473934ADB4Q27021268-6825FBF0-39FD-41C9-981E-05E1585F0422Q27022715-13131A41-CE63-452D-B0E7-856CB5B39E5CQ27022821-C970658A-122A-41D0-BB57-04C1BE6167B9Q28066240-4339E886-BC28-41E9-AC24-6CBC388AA63EQ28066293-ECC4D70D-D494-4F53-A0D6-40C212608314Q28068134-D6986D44-A063-4613-B567-D5F709CBB59EQ28068956-089FE9E5-77F1-4DF6-86BA-AC5CB0542176Q28071795-1225B925-BD47-474B-B688-26B2B63F0578Q28071912-D8E875B0-D242-44F8-820D-5BDB1C37F522Q28072081-9390D3DD-A9ED-4AA9-980E-DA929FA37E4AQ28072149-CFDAC36E-2800-47E3-8A73-2DAC605DE101
P2860
Alpha emitter radium-223 and survival in metastatic prostate cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Alpha emitter radium-223 and survival in metastatic prostate cancer
@ast
Alpha emitter radium-223 and survival in metastatic prostate cancer
@en
type
label
Alpha emitter radium-223 and survival in metastatic prostate cancer
@ast
Alpha emitter radium-223 and survival in metastatic prostate cancer
@en
prefLabel
Alpha emitter radium-223 and survival in metastatic prostate cancer
@ast
Alpha emitter radium-223 and survival in metastatic prostate cancer
@en
P2093
P50
P3181
P356
P1476
Alpha emitter radium-223 and survival in metastatic prostate cancer
@en
P2093
A Chodacki
ALSYMPCA Investigators
C G O'Bryan-Tear
D Bottomley
D C Johannessen
D Heinrich
I Syndikus
P304
P3181
P356
10.1056/NEJMOA1213755
P407
P577
2013-07-01T00:00:00Z